Type 2 diabetes therapy: A pathophysiologically based approach

Postgraduate Medicine

Volumn 111, Issue 3, 2002, Pages 83-95

  Mayerson, Adam B ^a   Inzucchi, Silvio E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DIABETES MELLITUS; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG PREFERENCE; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SUSTAINED RELEASE PREPARATION; WEIGHT GAIN;

EID: 0036122926     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.2002.03.1140     Document Type: Review

References (32)

1. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM
2. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients
3. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy
4. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus
5. Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: Quantitative contributions of pancreatic and peripheral responses to glucose homeostasis
6. Intact proinsulin and β-cell function in lean and obese subjects with and without type 2 diabetes
7. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
8. Standards of medical care for patients with diabetes mellitus
9. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
10. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients
11. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
12. Mechanism of improvement in glucose metabolism after chronic glyburide therapy
13. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: A mixed blessing?
14. The Achilles heel of the University Group Diabetes Program
15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
16. Glimepiride, a new once-daily sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
17. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
18. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients
19. Repaglinide in type 2 diabetes: A 24-week, fixed-dose efficacy and safety study
20. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
21. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
22. Mechanism by which metformin reduces glucose production in type 2 diabetes
23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
24. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
25. Acarbose: An update of its pharmacology and therapeutic use in diabetes mellitus
26. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: Placebo-controlled dose-comparison study
27. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
28. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes
29. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
30. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice
31. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
32. Nonhypoglycemic effects of thiazolidinediones